Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2019

View Archived Issues

Novel bis-indole-derived NR4A1 antagonists inhibit breast cancer cell growth in vitro and in vivo

Development of a new class of indazole-based MRA by modern CH functionalization chemistry

Microbiome metabolites modulate neonatal asthma risk

Zinc finger RNA binding protein found to be potent oncogene in colorectal and liver cancers

OXPHOS-dependent population of poor outcome AML can be targeted with the ERBB2 inhibitor mubritinib

Excell Biotech advances HSV vaccine EXD-12 through preclinical testing

PSLNR, an androgen-receptor prostate-specific lncRNA, is involved in prostate cancer progression

CARB-X funds BB100 to develop a unique monoclonal antibody against E. coli infection

FDA grants approval for new monotherapy indication for Keytruda

Turning Point Therapeutics initiates phase I clinical study of TPX-0022

Jaktinib demonstrates promising safety and PK in healthy volunteers

Developmental biliary agenesis in ALGS is reversible via restoration of Jagged/Notch

Researchers investigate dose optimization for levornidazole

Kymera Therapeutics patents CRBN inhibitors

Sage Therapeutics identifies new GABA-A receptor modulators

Medshine Discovery presents KRAS mutant inhibitors

New phase II trial studies IPI-549 with nivolumab in advanced urothelial carcinoma

IND open for phase II study of ELX-02 in cystic fibrosis

Roche synthesizes gamma-secretase inhibitors

MannKind advances pediatric study of Afrezza into final cohort

DSMB recommends continuation of phase II study of ANAVEX 2-73 for Rett syndrome

Sichuan Kelun-Biotech Biopharmaceutical describes IDO1 inhibitors

Aronora opens phase II study of AB-002 in end-stage renal disease patients on chronic hemodialysis

Sickle cell disease: Editing small group of cells leads to big-enough effects